Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
697 11 |
Ultima descărcare din IBN: 2022-08-31 16:06 |
Căutarea după subiecte similare conform CZU |
615.2:616-006-085 (1) |
Medicamentele potrivit acţiunii lor principale (395) |
Patologie. Medicină clinică (6963) |
SM ISO690:2012 MORARU, Sergiu, ODOBESCU, Oxana. Preparatele inhibitoare ale angiogenezei tumorale – o nouă tendință în tratamentul tumorilor solide. In: Revista ştiinţifico-practică ”Info-Med” , 2016, nr. 2(28-2), pp. 255-258. ISSN 1810-3936. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Revista ştiinţifico-practică ”Info-Med” | |||||||
Numărul 2(28-2) / 2016 / ISSN 1810-3936 | |||||||
|
|||||||
CZU: 615.2:616-006-085 | |||||||
Pag. 255-258 | |||||||
|
|||||||
Descarcă PDF | |||||||
Rezumat | |||||||
Angiogenesis (from gr. Angeion blood vessel and genesis - birth) is the process of forming new vessels, from the network of existing vessels. The phenomenon begins during fetal life and continues in child and adult, ensuring growth and development. Aberrations of phenomenon can be a condition sin quo non in the pathogenesis of diseases such as cancer. Angiogenesis inhibitors are revolutionary products called molecular targeted therapies aimed to inhibiting the progression of essential processes in carcinogenesis, one of which is angiogenesis. The result may be achieved using monoclonal antibodies - bevacizumab, cetuximab, or small molecule drugs - sunitinib, pazopanib, everolimus, etc. |
|||||||
Cuvinte-cheie angiogenesis, cancer, molecular targeted therapy, bevacizumab |
|||||||
|